SCHEMBL4858645

SCHEMBL4858645

O=C(CCl)Nc1nc2cc(Cl)ccc2o1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 1/20 0.63
FFAR2 O15552 1/20 0.57
USP30 Q70CQ3 1/20 0.55
KCNH2 Q12809 2/20 0.55
KMT2A Q03164 2/20 0.55
CSNK1D P48730 1/20 0.55
MEN1 O00255 1/20 0.55
GAA P10253 1/20 0.55
FBP1 P09467 6/20 0.52
LMNA P02545 1/20 0.50
TP53 P04637 1/20 0.50
CASP3 P42574 2/20 0.48
NPC1 O15118 1/20 0.48
POLB P06746 1/20 0.48
RAB9A P51151 1/20 0.48
SENP7 Q9BQF6 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HDAC1 Q13547 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14697189 0.89 ANO1 (0.61) ANO1FFAR2USP30KCNH2KMT2A
SCHEMBL3777315 0.84 KCNH2 (0.63) ANO1FFAR2USP30KCNH2KMT2A
SCHEMBL4920542 0.83 CSNK1D (0.73) ANO1FFAR2KCNH2KMT2ACSNK1D
SCHEMBL14047971 0.82 FFAR2 (0.60) ANO1FFAR2USP30KCNH2KMT2A
SCHEMBL16021385 0.81 CSNK1D (0.67) KMT2ACSNK1DMEN1GAATP53
SCHEMBL18824198 0.79 FFAR2 (0.59) ANO1FFAR2KCNH2KMT2AMEN1
SCHEMBL24349097 0.78 ANO1 (1.00) ANO1KMT2AMEN1TP53
SCHEMBL5550664 0.78 ANO1 (0.73) ANO1FFAR2KMT2AMEN1TP53
SCHEMBL8125417 0.78 SCD (0.64) ANO1FFAR2KCNH2KMT2ACSNK1D
SCHEMBL7431194 0.77 ANO1 (0.54) ANO1FFAR2USP30KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2020-04-07 US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 US disclosed
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE 2017-05-25 US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 US disclosed
US-9598402-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections SOUTHERN RESEARCH INSTITUTE (US) 2017-03-21 US disclosed
EP-2744787-B1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RES INST (US) 2016-11-02 EP disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 US disclosed
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2014-09-11 US disclosed
EP-2744787-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS Southern Research Institute (US) 2014-06-25 EP disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 WO disclosed
WO-2013025508-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS SOUTHERN RESEARCH INSTITUTE (US) 2013-02-21 WO disclosed
US-7407960-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2008-08-05 US disclosed
EP-1806346-A1 Substituted piperazine compounds and their use as fatty acid oxidation inhibitors CV THERAPEUTICS, INC. (US) 2007-07-11 EP disclosed
US-20070004751-A1 Substituted heterocyclic compounds ELZEIN ELFATIH 2007-01-04 US disclosed
US-7125876-B2 Substituted heterocyclic compounds CV THERAPEUTICS, INC. (US) 2006-10-24 US disclosed
EP-1567525-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2005-08-31 EP disclosed
US-20040152890-A1 Substituted heterocyclic compounds CV THERAPEUTICS, INC. 2004-08-05 US disclosed
WO-2004052887-A2 SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS CV THERAPEUTICS, INC. (US) 2004-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256753-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS HAVCR2, EIF2AK2, GLS2 ANO1 4045/4885FFAR2 4524/4885USP30 3142/4885
US-20170144978-A1 QUINAZOLINONE ANALOGS AND USE OF QUINAZOLINONE ANALOGS FOR TREATING OR PREVENTING CERTAIN VIRAL INFECTIONS ZC3HAV1, EIF2AK2, GTF3C3 ANO1 4282/4885FFAR2 4766/4885USP30 2305/4885
US-20040152890-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ANO1 402/4885FFAR2 1830/4885USP30 4434/4885
US-10611733-B2 Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections ZC3HAV1, EIF2AK2, GTF3C3 ANO1 4282/4885FFAR2 4766/4885USP30 2305/4885
US-20070004751-A1 Substituted heterocyclic compounds KCNH1, SDHA, COQ8A ANO1 305/4885FFAR2 1753/4885USP30 4510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.